Mednet Logo
HomeRadiation Oncology
Radiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

How do you deal with an interruption in definitive EBRT for prostate cancer?

1
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Virginia Commonwealth University Medical Center

The evidence that total treatment time matters in prostate cancer is pretty weak. In general, I would proceed as planned when the patient is able to resume without increasing the intended total dose. In this case, I would prefer not to stop at 60 Gy, as that dose probably would not be curative. Unle...

How do you approach staging and treatment for a p16+ nasopharyngeal SCC?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Memorial Sloan Kettering Cancer Center

First question is whether it is strictly p16 positive and confirmed EBER ISH negative. If so, I treat it like p16 positive oropharyngeal cancer with chemoradiation. I don't give adjuvant chemo. All the adjuvant chemo or induction chemo data is for EBER ISH positive nasopharyngeal carcinoma.

Would you offer post-operative radiation therapy for a pseudoendocrine sarcoma with a CTNNB mutation of the spine that has been resected with a positive margin?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · The Ohio State University - James Cancer Hospital and Solove Research Institute

I am not aware of any histology-specific data that would alter the otherwise standard approach to such a situation. If I were seeing such a patient, I would: Get MRI to confirm no gross residual disease. Ask the surgeon to re-resect for R0 margins, if at all possible. Treat to 60 Gy postop if so, ...

Would differentiating between embryonal vs alveolar rhabdomyosarcoma of the nasal cavity change your neoadjuvant chemotherapy regimen or make you consider neoadjuvant radiation in a locally advanced pleomorphic RMS?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Texas MD Anderson Cancer Center

The historic Embryonal vs. Alveolar differentiation is being replaced by a (PAX-FOXO) fusion positive vs. negative classification given the prognostic significance. In either case, the chemotherapy regimen is not likely to change in an adult patient. Pleomorphic RMS on the other hand, more common in...

When, if ever, do you recommend concurrent chemotherapy with definitive RT for early stage oral cavity squamous cell carcinoma?

2
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Florida

Early stage oral cavity cancers are best treated with surgery or definitive RT including brachytherapy. If brachytherapy is not feasible and surgery is not an option, I would consider adding cisplatin but it would not be my first choice.

How would you treat an isolated pancreatic adenocarcinoma recurrence in the post-op bed with progression through chemotherapy and no prior radiation therapy?

3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Memorial Sloan-Kettering Cancer Center

These tumors can usually be treated more easily with definitive doses of radiation because the duodenum has been removed. We are presenting our 69pt experience treating isolated local recurrence with ablative doses at ASTRO this year. Doses: 100Gy BED, (50Gy/5#, 67.5/15#, or 75Gy/25#). Median OS: 26...

What radiation lung dose constraints should be used for a standard fractionation plan in patients recovering from recent immunotherapy induced pneumonitis?

3
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Louisville

Since immune mediated pneumonitis tends to be a more global/diffuse process, I'm much more concerned about low dose spillage throughout the lung. IMRT is so commonly used for treating lung cancer so we often forget that trying to minimize low dose spillage (i.e. V5) may be better accomplished throug...

What is the best approach to organ confined squamous cell cancer of the prostate?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · The University of Texas Health Science Center at San Antonio

This is a very unusual situation in the US and other developed countries. Most of the patients with this histology tend to have other chronic illnesses to the pelvis prompting the development of this chronic inflammatory driven disease. As such, they can represent difficult situations to treat. From...

When do you offer a boost for patients receiving 5 fraction whole breast radiation as per UK FAST Forward?

6
4 Answers

Mednet Member
Mednet Member
Radiation Oncology · Northeast Alabama Regional Medical Center

Any data (convincingly) supporting the use of boost comes from the non-hypofx era. In the START A/B trials (which included many "traditionally boostable" patients), boost/no-boost outcomes were analyzed (left up to each center's/doc's preference), and boost had an almost perfectly zero effect on out...

How would you treat a biopsy-proven isolated uterine cervix metastasis of adenocarcinoma from a known colon cancer primary, previously stage IIIb at diagnosis two years prior?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Sunnybrook Health Sciences Centre

We have dealt with few similar cases in the past few years. The overall management will depend on the patient's prior history - did she get any neo-adj or adj radiation within the pelvis for prior cancer? How large is the cervix metastasis? A multi-disciplinary management is paramount with involveme...